e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Aetiology and outcomes of infective exacerbations of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia
A. Singanayagam, A. Akram, J. Chalmers, A. Hill (United Kingdom)
Source:
Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD
Session:
Aetiology and outcomes of infective exacerbations of COPD
Session type:
Oral Presentation
Number:
3845
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Singanayagam, A. Akram, J. Chalmers, A. Hill (United Kingdom). Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia. Eur Respir J 2010; 36: Suppl. 54, 3845
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
Inhaled corticosteroid therapy on admission of hospitalized patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids
Source: Annual Congress 2007 - Epidemiology of COPD
Year: 2007
Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019
Year: 2019
Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019
Year: 2019
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Use of long acting bronchodilators and inhaled corticosteroids within 30-days of discharge in older adults hospitalized for AECOPD
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002
Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis
Year: 2012
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Risks of pneumonia in asthmatic patients taking inhaled corticosteroids
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Association of COPD inhaled medication adherence with hospitalization for acute exacerbation of COPD (AECOPD)
Source: International Congress 2017 – COPD management
Year: 2017
Change of inhaled medications during hospital admissions for acute exacerbation of COPD
Source: International Congress 2018 – Nutrition and metabolic syndrome in COPD
Year: 2018
Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?
Source: Eur Respir J 2011; 37: 1-3
Year: 2011
Characteristics of COPD patients treated with inhaled corticosteroid in primary care
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept